MARLBOROUGH, Mass. — April 16, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the second patient was dosed in the Company’s Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient is recovering uneventfully.
“We are very pleased to announce that the treatment of the second dry AMD patient went very well, without any complications,” said Gary Rabin, chairman and CEO of ACT. “We are delighted with our ongoing progress in all of our clinical trials using our stem cell-derived RPE cells to treat forms of macular degeneration. So far, there have not been any complications or side effects due to the stem cell-derived RPE cells, and we will continue monitoring the patients for safety, tolerability and efficacy of this therapy.”
The dry AMD trial is one of three clinical trials being carried out by the company in the U.S. and in Europe. Each trial will enroll 12 patients, with cohorts of three patients in an ascending dosage format.
在美国和欧洲同时还有2项相关实验正在进行。三项实验中将招募12名病人，群组内注射剂量逐渐递增。
These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or Stargardt’s macular dystrophy (SMD) at 12 months, the study’s primary endpoint.
